Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor α antibody)

British Journal of Dermatology

Volumn 155, Issue 3, 2006, Pages 617-620

  Osborne, G E N ^a   Pagliuca, A ^a   Ho, A ^a   Du Vivier, A W P ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Adult T cell leukaemia lymphoma; Daclizumab; Erythoderma; Human T cell lymphotropic virus type I

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CHLORAMBUCIL; DACLIZUMAB; EMOLLIENT AGENT; ETRETIN; IDARUBICIN; INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; PREDNISOLONE; STEROID; THALIDOMIDE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE REGIMEN; ERYTHRODERMA; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN TISSUE; INGUINAL LYMPH NODE; MALE; PRIORITY JOURNAL; SEZARY LIKE SYNDROME; SEZARY SYNDROME; SKIN BIOPSY; T CELL LEUKEMIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 33747041602     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07355.x     Document Type: Article

References (19)

1. Poiesz BJ, Ruscetti FW, Reitz MS et al. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. Nature 1981; 294:268-71.
2. Pawson R, Mufti GJ, Pagliuca A. The management of adult T cell leukaemia/lymphoma. Br J Haematol 1998; 100:453-8.
3. Uchiyama T, Yodoi J, Sagawa K et al. Adult T-cell leukaemia: clinical and haematologic features of 16 cases. Blood 1997; 50:481-92.
4. Edlich RF, Arnette JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-1 (HTLV-1). J Emerg Med 2000; 18:109-19.
5. Catovsky D, Rose M, Goolden AWG et al. Adult T-cell lymphoma in Blacks from the West Indies. Lancet 1982; i:639-43.
6. Blattner WA. Human retroviruses: their role in cancer. Proc Assoc Am Physicians 1999; 111:563-72.
7. Whitaker SJ, Ng YL, Rustin M et al. HTLV-1-associated cutaneous disease: a clinicopathological and molecular study of patients from the UK. Br J Haematol 1993; 128:483-92.
8. Ikai K, Uchiyama T, Maeda M, Takigawa M. Sézary-like syndrome in a 10 year old girl with serologic evidence of human T-cell lymphotropic virus type 1 infection. Arch Dermatol 1987; 123:1351-5.
9. Broder SL, Bunn PA, Jaffe ES et al. T-cell lymphoproliferative syndrome associated with human T-cell leukaemia lymphoma virus. Ann Intern Med 1984; 100:543-57.
10. Di Caudo DJ, Perniciaro C, Trace Worrell J et al. Clinical and histologic spectrum of human T-cell lymphotropic virus type-1 involving the skin. J Am Acad Dermatol 1996; 34:69-76.
11. Maeda K, Takahashi M. Characterisation of skin infiltrating cells in adult T-cell leukaemia/lymphoma (ATLL): clinical, histological and immunohistochemical studies on eight cases. Br J Dermatol 1989; 189:603-12.
12. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia/lymphoma. Br J Haematol 1991; 79:428-37.
13. Farcet JP, Lebargy F, Lavignac C et al. Constitutive IL-2 expression in HTLV-1-infected leukaemic T-cell lines. Clin Exp Immunol 1991; 84:415-21.
14. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Immunodeficiency Viruses and Human T-cell Lymphotropic Viruses. Lyon: IARC, 1996.
15. Waldman TA, White JD, Goldman CK et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus 1-induced adult T-cell leukaemia. Blood 1993; 82:1701-12.
16. Waldman TA, White JD, Carrasquillo JA et al. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukaemia with yttrium-90-labelled anti-Tac. Blood 1995; 86:4063-75.
17. Wiseman LR, Faulds D. Daclizumab. A review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999; 58:1029-42.
18. Junghans RP, Waldman TA, Landolfi NF et al. Anti-Tac-H, a humanised antibody to the interleukin-2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50:1495-502.
19. Phillips KE, Herring B, Wilson LA et al. IL-2r alpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukaemia by a mechanism other than blockade of IL-2/IL-2r alpha interaction. Cancer Res 2000; 60:6977-84.